Adjuvant Chemo Plus CRT Best in Nasopharyngeal Carcinoma

Share this content:
Adjuvant Chemo Plus CRT Best in Nasopharyngeal Carcinoma
Adjuvant Chemo Plus CRT Best in Nasopharyngeal Carcinoma

MONDAY, Dec. 19, 2016 (HealthDay News) -- For nonmetastatic nasopharyngeal carcinoma, the addition of adjuvant chemotherapy (AC) to chemoradiotherapy (CRT) is associated with the highest survival benefit, according to research published online Dec. 5 in the Journal of Clinical Oncology.

Laureen Ribassin-Majed, Ph.D., from the Université Paris-Saclay, and colleagues compared available treatments using individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database. They considered all randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma; data were included from 20 trials and 5,144 patients.

The researchers found that the three treatments with the highest probability of benefit on overall survival were CRT followed by AC (CRT-AC), CRT, and induction chemotherapy followed by CRT (IC-CRT), with hazard ratios of 0.65 (95 percent confidence interval [CI], 0.56 to 0.75), 0.77 (95 percent CI, 0.64 to 0.92), and 0.81 (95 percent CI, 0.63 to 1.04), compared with RT alone. For CRT-AC versus CRT alone, the hazard ratios were 0.85 (95 percent CI, 0.68 to 1.05) for overall survival, 0.81 (95 percent CI, 0.66 to 0.98) for progression-free survival, 0.70 (95 percent CI, 0.48 to 1.02) for locoregional control, and 0.87 (95 percent CI, 0.61 to 1.25) for distant control (DC).

"The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points," the authors write. "The addition of IC to CRT achieved the highest effect on DC."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Influenza Vaccine 48 Percent Effective Overall

CDC: Influenza Vaccine 48 Percent Effective Overall

More severe H3N2 strain a factor in reduced coverage

D.C. Zika Tests Were Flawed

D.C. Zika Tests Were Flawed

One of the issues with tests was a mathematical error

Experts Warn of Health Threats From Climate Change

Experts Warn of Health Threats From Climate Change

Additional 250,000 deaths/year projected from heat stress, malnutrition, infectious diseases

is free, fast, and customized just for you!

Already a member?

Sign In Now »